biOasis Technologies Inc. (TSX:V.BTI) announced today an update on the advancement of its anti-cancer product candidate BT2111. BT2111 is a brain- penetrating conjugate of trastuzumab (Herceptin®) and our Transcend vector designed to treat brain metatastsis of HER2+ breast cancer. Based on the exceptional data announced on February 7th of this year, which show both a remarkable reduction on brain tumors as well as tumor size, the company along with its expert industry advisors has now developed the road map to take this program to the next stage of preclinical development.
biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2013 TSX Venture 50® companies. The 2013 TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada's junior stock exchange.
biOasis Announces Positive Anti-Tumour Efficacy Data
biOasis Transcend-Herceptin® Conjugate (BT2111) Significantly Reduces the Number and Size of Metastatic HER2+ Breast Cancer Tumors in the Brain
biOasis Technologies Inc. announced today that its Transcend-Herceptin® Conjugate (BT2111) product candidate (a proprietary conjugate of Roche’s anti-cancer antibody trastuzumab (Herceptin®) and Transcend, biOasis brain delivery vector) reduced the number of metastatic human HER2+ breast cancer tumors in the brains of test animals by 68% when compared to untreated control animals. The tumors that remained after treatment were 57% smaller than those in the untreated control animals. In contrast, Herceptin alone had no effect on reducing the number of tumors and was associated with only a slight (15%) reduction in tumor size when compared to untreated control animals. These results provide clear evidence of the potential of the biOasis Transcend-Herceptin® Conjugate (BT2111) for treating brain metastasis.